$MDIT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Medite Cancer Diagnostics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Medite Cancer Diagnostics, Inc.. Get notifications about new insider transactions in Medite Cancer Diagnostics, Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23 2018 | MDIT | Medite Cancer Diag ... | ABELES JOHN H | Buy | P | 0.08 | 266,667 | 20,000 | 1,566,852 | 1.3 M to 1.6 M (+20.51 %) | |
| Oct 23 2018 | MDIT | Medite Cancer Diag ... | ABELES JOHN H | Buy | J | 0.00 | 40,000 | 0 | 1,300,185 | 1.3 M to 1.3 M (+3.17 %) | |
| Oct 19 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 80,000 | 6,000 | 2,213,333 | 2.1 M to 2.2 M (+3.75 %) | |
| Oct 19 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 8,973,333 | 673,000 | 36,611,163 | 27.6 M to 36.6 M (+32.47 %) | |
| Jul 30 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 1,100,000 | 82,500 | 29,771,162 | 28.7 M to 29.8 M (+3.84 %) | |
| Jul 30 2018 | MDIT | Medite Cancer Diag ... | Von Rump Stephen L. | CEO / CFO | Buy | P | 0.08 | 133,333 | 10,000 | 266,666 | 133.3 K to 266.7 K (+100.00 %) |
| Jul 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 400,000 | 30,000 | 28,671,162 | 28.3 M to 28.7 M (+1.41 %) | |
| Jul 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 6,933,333 | 520,000 | 28,271,162 | 21.3 M to 28.3 M (+32.49 %) | |
| Jul 10 2018 | MDIT | Medite Cancer Diag ... | ABELES JOHN H | Buy | P | 0.08 | 400,000 | 30,000 | 2,608,381 | 2.2 M to 2.6 M (+18.11 %) | |
| Jul 05 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 1,333,334 | 100,000 | 21,337,830 | 20 M to 21.3 M (+6.67 %) | |
| Jul 05 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 8,000,000 | 600,000 | 20,004,496 | 12 M to 20 M (+66.64 %) | |
| May 08 2018 | MDIT | Medite Cancer Diag ... | FORTUNOFF GREGORY | Option Exercise | P | 0.08 | 100,000 | 7,500 | 100,000 | ||
| May 08 2018 | MDIT | Medite Cancer Diag ... | FORTUNOFF GREGORY | Buy | P | 0.75 | 1,333,334 | 1,000,001 | 1,533,334 | 200 K to 1.5 M (+666.67 %) | |
| Feb 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Option Exercise | A | 0.50 | 600,000 | 300,000 | 912,579 | ||
| Feb 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Option Exercise | P | 0.50 | 312,579 | 156,290 | 312,579 | ||
| Feb 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | I | 0.08 | 1,333,333 | 100,000 | 12,004,496 | 10.7 M to 12 M (+12.49 %) | |
| Feb 12 2018 | MDIT | Medite Cancer Diag ... | Lewis William Austin IV | Buy | P | 0.08 | 10,666,667 | 800,000 | 10,671,163 | 4.5 K to 10.7 M (+237,247.93 %) | |
| Nov 16 2017 | MDIT | Medite Cancer Diag ... | Weisman Susan | CHIEF FINANCIAL OFF ... | Grant | A | 0.81 | 200,000 | 162,000 | 200,000 | 0 to 200 K |
| Oct 05 2015 | MDIT | Medite Cancer Diag ... | Ott Michaela | Chief Executive Off ... | Buy | P | 0.00 | 156,250 | 0 | 7,500,000 | 7.3 M to 7.5 M (+2.13 %) |
| Oct 05 2015 | MDIT | Medite Cancer Diag ... | Ott Michaela | Chief Executive Off ... | Buy | P | 0.00 | 156,250 | 0 | 7,500,000 | 7.3 M to 7.5 M (+2.13 %) |
| Oct 05 2015 | MDIT | Medite Cancer Diag ... | Ott Michael Egbert | President and COO | Buy | P | 0.00 | 156,250 | 0 | 7,500,000 | 7.3 M to 7.5 M (+2.13 %) |
| Oct 05 2015 | MDIT | Medite Cancer Diag ... | Ott Michael Egbert | President and COO | Buy | P | 0.00 | 156,250 | 0 | 7,500,000 | 7.3 M to 7.5 M (+2.13 %) |
| May 28 2013 | MDIT | Medite Cancer Diag ... | Carbonell Xavier | Director | Grant | A | 0.02 | 919,234 | 14,248 | 6,569,823 | 5.7 M to 6.6 M (+16.27 %) |
| May 22 2013 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Grant | A | 0.02 | 162,500,000 | 3,250,000 | 167,524,501 | 5 M to 167.5 M (+3,234.15 %) |
| Jun 28 2012 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.02 | 1,301,353 | 26,027 | 5,024,501 | 3.7 M to 5 M (+34.95 %) |
| Feb 16 2012 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.02 | 2,187,500 | 32,813 | 3,723,148 | 1.5 M to 3.7 M (+142.45 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | M | 0.25 | 10,000 | 2,500 | 0 | |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | X | 0.25 | 12,500 | 3,125 | 0 | |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | X | 0.25 | 37,500 | 9,375 | 0 | |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | M | 0.25 | 25,000 | 6,250 | 0 | |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | M | 0.25 | 400,000 | 100,000 | 0 | |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Grant | A | 0.00 | 59,459 | 0 | 1,110,876 | 1.1 M to 1.1 M (+5.66 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | M | 0.25 | 10,000 | 2,500 | 1,051,417 | 1 M to 1.1 M (+0.96 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | X | 0.25 | 12,500 | 3,125 | 1,041,417 | 1 M to 1 M (+1.21 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | X | 0.25 | 37,500 | 9,375 | 1,028,917 | 991.4 K to 1 M (+3.78 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | M | 0.25 | 25,000 | 6,250 | 991,417 | 966.4 K to 991.4 K (+2.59 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.25 | 400,000 | 100,000 | 966,417 | 566.4 K to 966.4 K (+70.62 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.34 | 5,000 | 1,700 | 566,417 | 561.4 K to 566.4 K (+0.89 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.41 | 4,000 | 1,640 | 561,417 | 557.4 K to 561.4 K (+0.72 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.45 | 5,000 | 2,250 | 557,417 | 552.4 K to 557.4 K (+0.91 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.45 | 5,000 | 2,250 | 552,417 | 547.4 K to 552.4 K (+0.91 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.47 | 3,000 | 1,410 | 547,417 | 544.4 K to 547.4 K (+0.55 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.35 | 5,000 | 1,750 | 1,242,950 | 1.2 M to 1.2 M (+0.40 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.42 | 3,000 | 1,260 | 1,237,950 | 1.2 M to 1.2 M (+0.24 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.43 | 60,800 | 26,144 | 1,234,950 | 1.2 M to 1.2 M (+5.18 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.44 | 10,000 | 4,400 | 1,174,150 | 1.2 M to 1.2 M (+0.86 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.44 | 18,000 | 7,920 | 1,164,150 | 1.1 M to 1.2 M (+1.57 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.45 | 5,000 | 2,250 | 1,146,150 | 1.1 M to 1.1 M (+0.44 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.45 | 1,000 | 450 | 1,141,150 | 1.1 M to 1.1 M (+0.09 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.44 | 22,000 | 9,680 | 1,140,150 | 1.1 M to 1.1 M (+1.97 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.48 | 25,000 | 12,000 | 1,118,150 | 1.1 M to 1.1 M (+2.29 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.56 | 40,000 | 22,400 | 1,093,150 | 1.1 M to 1.1 M (+3.80 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.55 | 7,500 | 4,125 | 1,053,150 | 1 M to 1.1 M (+0.72 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.51 | 30,000 | 15,300 | 1,045,650 | 1 M to 1 M (+2.95 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.52 | 11,000 | 5,720 | 1,015,650 | 1 M to 1 M (+1.09 %) |
| May 05 2009 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.55 | 10,000 | 5,500 | 1,004,650 | 994.7 K to 1 M (+1.01 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.26 | 10,000 | 2,600 | 544,417 | 534.4 K to 544.4 K (+1.87 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.29 | 5,000 | 1,450 | 534,417 | 529.4 K to 534.4 K (+0.94 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.23 | 5,000 | 1,150 | 529,417 | 524.4 K to 529.4 K (+0.95 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.22 | 25,000 | 5,500 | 524,417 | 499.4 K to 524.4 K (+5.01 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.32 | 4,000 | 1,280 | 499,417 | 495.4 K to 499.4 K (+0.81 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.28 | 32,000 | 8,960 | 495,417 | 463.4 K to 495.4 K (+6.91 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.24 | 21,000 | 5,040 | 463,417 | 442.4 K to 463.4 K (+4.75 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.18 | 10,000 | 1,800 | 442,417 | 432.4 K to 442.4 K (+2.31 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.19 | 3,000 | 570 | 432,417 | 429.4 K to 432.4 K (+0.70 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.21 | 36,000 | 7,560 | 429,417 | 393.4 K to 429.4 K (+9.15 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.26 | 7,000 | 1,820 | 393,417 | 386.4 K to 393.4 K (+1.81 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.24 | 1,500 | 360 | 386,417 | 384.9 K to 386.4 K (+0.39 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.32 | 500 | 160 | 384,917 | 384.4 K to 384.9 K (+0.13 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.27 | 3,000 | 810 | 384,417 | 381.4 K to 384.4 K (+0.79 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.30 | 1,500 | 450 | 381,417 | 379.9 K to 381.4 K (+0.39 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.33 | 500 | 165 | 379,917 | 379.4 K to 379.9 K (+0.13 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.28 | 3,000 | 840 | 379,417 | 376.4 K to 379.4 K (+0.80 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.31 | 1,000 | 310 | 376,417 | 375.4 K to 376.4 K (+0.27 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.26 | 5,000 | 1,300 | 375,417 | 370.4 K to 375.4 K (+1.35 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.29 | 15,000 | 4,350 | 370,417 | 355.4 K to 370.4 K (+4.22 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.29 | 5,000 | 1,450 | 994,650 | 989.7 K to 994.7 K (+0.51 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.31 | 17,500 | 5,425 | 989,650 | 972.2 K to 989.7 K (+1.80 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.17 | 62,500 | 10,625 | 972,150 | 909.7 K to 972.2 K (+6.87 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.25 | 500 | 125 | 909,650 | 909.2 K to 909.7 K (+0.05 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.30 | 500 | 150 | 909,150 | 908.7 K to 909.2 K (+0.06 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.25 | 330,400 | 82,600 | 908,650 | 578.3 K to 908.7 K (+57.14 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.30 | 17,500 | 5,250 | 578,250 | 560.8 K to 578.3 K (+3.12 %) |
| Dec 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.27 | 30,000 | 8,100 | 560,750 | 530.8 K to 560.8 K (+5.65 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.52 | 500 | 260 | 355,417 | 354.9 K to 355.4 K (+0.14 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.67 | 500 | 335 | 354,917 | 354.4 K to 354.9 K (+0.14 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.62 | 1,000 | 620 | 354,417 | 353.4 K to 354.4 K (+0.28 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.57 | 1,000 | 570 | 353,417 | 352.4 K to 353.4 K (+0.28 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.49 | 3,000 | 1,470 | 352,417 | 349.4 K to 352.4 K (+0.86 %) |
| Oct 20 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.51 | 2,000 | 1,020 | 349,417 | 347.4 K to 349.4 K (+0.58 %) |
| Sep 23 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.73 | 4,000 | 2,920 | 530,750 | 526.8 K to 530.8 K (+0.76 %) |
| Sep 23 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.76 | 7,500 | 5,725 | 526,750 | 519.3 K to 526.8 K (+1.44 %) |
| Sep 23 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.83 | 12,500 | 10,385 | 519,250 | 506.8 K to 519.3 K (+2.47 %) |
| Sep 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 0.95 | 4,000 | 3,800 | 506,750 | 502.8 K to 506.8 K (+0.80 %) |
| Sep 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 1.00 | 5,000 | 4,990 | 502,750 | 497.8 K to 502.8 K (+1.00 %) |
| Sep 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 1.23 | 4,500 | 5,530 | 497,750 | 493.3 K to 497.8 K (+0.91 %) |
| Sep 04 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 1.21 | 10,000 | 12,135 | 493,250 | 483.3 K to 493.3 K (+2.07 %) |
| Aug 14 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Option Exercise | A | 2.06 | 10,000 | 20,600 | 10,000 | |
| Aug 14 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | A | 2.06 | 10,000 | 20,600 | 10,000 | |
| Jul 22 2008 | MDIT | Medite Cancer Diag ... | MILLEY ALEXANDER M | Director | Option Exercise | X | 1.00 | 195,192 | 195,192 | 0 | |
| Jul 22 2008 | MDIT | Medite Cancer Diag ... | MILLEY ALEXANDER M | Director | Option Exercise | X | 1.00 | 154,808 | 154,808 | 0 | |
| Jul 22 2008 | MDIT | Medite Cancer Diag ... | MILLEY ALEXANDER M | Director | Buy | X | 1.00 | 195,192 | 195,192 | 802,950 | 607.8 K to 803 K (+32.12 %) |
| Jul 22 2008 | MDIT | Medite Cancer Diag ... | MILLEY ALEXANDER M | Director | Buy | X | 1.00 | 68,804 | 68,804 | 607,758 | 539 K to 607.8 K (+12.77 %) |
| Jul 31 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO & CFO | Buy | P | 1.36 | 15,000 | 20,411 | 483,250 | 468.3 K to 483.3 K (+3.20 %) |
| Jul 31 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO & CFO | Buy | P | 1.35 | 25,000 | 33,750 | 468,250 | 443.3 K to 468.3 K (+5.64 %) |
| May 07 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Buy | P | 2.95 | 20,000 | 59,000 | 3,240,500 | 3.2 M to 3.2 M (+0.62 %) |
| May 07 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Buy | P | 2.65 | 20,000 | 53,000 | 3,220,500 | 3.2 M to 3.2 M (+0.62 %) |
| Apr 25 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.22 | 10,000 | 22,200 | 443,250 | 433.3 K to 443.3 K (+2.31 %) |
| Apr 25 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.09 | 10,000 | 20,900 | 433,250 | 423.3 K to 433.3 K (+2.36 %) |
| Apr 25 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.12 | 12,500 | 26,500 | 423,250 | 410.8 K to 423.3 K (+3.04 %) |
| Apr 07 2008 | MDIT | Medite Cancer Diag ... | Taub Floyd Elliot | Director | Buy | P | 0.00 | 10,000 | 0 | 17,368 | 7.4 K to 17.4 K (+135.72 %) |
| Mar 27 2008 | MDIT | Medite Cancer Diag ... | SEVERSON CLINTON | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Mar 25 2008 | MDIT | Medite Cancer Diag ... | ABELES JOHN H | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Mar 26 2008 | MDIT | Medite Cancer Diag ... | Domanik Richard Anthony | President | Grant | A | 0.00 | 100,000 | 0 | 111,159 | 11.2 K to 111.2 K (+896.14 %) |
| Mar 25 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Grant | A | 0.00 | 100,000 | 0 | 3,200,500 | 3.1 M to 3.2 M (+3.23 %) |
| Mar 25 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Grant | A | 0.00 | 100,000 | 0 | 347,417 | 247.4 K to 347.4 K (+40.42 %) |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Option Exercise | P | 2.00 | 150,000 | 300,000 | 175,000 | |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Buy | P | 2.00 | 300,000 | 600,000 | 3,100,500 | 2.8 M to 3.1 M (+10.71 %) |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | Burns Daniel Joseph | Director | Buy | P | 1.85 | 20,000 | 37,000 | 2,800,500 | 2.8 M to 2.8 M (+0.72 %) |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Option Exercise | P | 2.00 | 50,000 | 100,000 | 475,000 | |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.00 | 45,000 | 90,000 | 247,417 | 202.4 K to 247.4 K (+22.23 %) |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.00 | 17,500 | 35,000 | 121,205 | 103.7 K to 121.2 K (+16.87 %) |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.00 | 12,500 | 25,000 | 12,500 | 0 to 12.5 K |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.00 | 12,500 | 25,000 | 12,500 | 0 to 12.5 K |
| Feb 01 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO and CFO | Buy | P | 2.00 | 12,500 | 25,000 | 12,500 | 0 to 12.5 K |
| Jan 07 2008 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CEO & CFO | Buy | P | 2.30 | 7,500 | 17,250 | 410,750 | 403.3 K to 410.8 K (+1.86 %) |
| Apr 12 2007 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CFO | Option Exercise | X | 0.10 | 505,794 | 50,579 | 0 | |
| Apr 12 2007 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CFO | Buy | X | 0.10 | 505,794 | 50,579 | 2,024,179 | 1.5 M to 2 M (+33.31 %) |
| Oct 04 2006 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Grant | A | 0.20 | 12,559,311 | 2,511,862 | 14,005,511 | 1.4 M to 14 M (+868.44 %) |
| Oct 02 2006 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | CFO | Option Exercise | A | 0.13 | 4,000,000 | 510,000 | 4,000,000 | |
| Oct 02 2006 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Option Exercise | A | 0.20 | 4,000,000 | 800,000 | 4,000,000 | |
| Oct 02 2006 | MDIT | Medite Cancer Diag ... | ABELES JOHN H | Director | Option Exercise | A | 0.20 | 625,000 | 125,000 | 625,000 | |
| Oct 21 2005 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Option Exercise | C | 0.10 | 569,000 | 56,900 | 0 | |
| Oct 21 2005 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Buy | C | 0.10 | 5,690,000 | 569,000 | 10,739,311 | 5 M to 10.7 M (+112.69 %) |
| Oct 19 2005 | MDIT | Medite Cancer Diag ... | MCCULLOGH ROBERT F JR | Chief Financial Off ... | Buy | P | 0.09 | 55,000 | 4,895 | 1,518,385 | 1.5 M to 1.5 M (+3.76 %) |
| Sep 09 2005 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Buy | P | 0.03 | 1,600,000 | 40,000 | 7,719,311 | 6.1 M to 7.7 M (+26.15 %) |
| Sep 09 2005 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Buy | P | 0.09 | 150,000 | 12,750 | 1,396,200 | 1.2 M to 1.4 M (+12.04 %) |
| Sep 30 2005 | MDIT | Medite Cancer Diag ... | WEISSBERG DAVID J | CEO | Buy | P | 0.10 | 50,000 | 5,000 | 1,446,200 | 1.4 M to 1.4 M (+3.58 %) |
| Jan 07 2005 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.09 | 10,000 | 860 | 210,000 | 200 K to 210 K (+5.00 %) |
| Sep 15 2004 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.10 | 45,000 | 4,500 | 140,000 | 95 K to 140 K (+47.37 %) |
| Sep 15 2004 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.10 | 5,000 | 475 | 95,000 | 90 K to 95 K (+5.56 %) |
| Sep 20 2004 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.11 | 20,000 | 2,200 | 200,000 | 180 K to 200 K (+11.11 %) |
| Sep 20 2004 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.11 | 40,000 | 4,400 | 180,000 | 140 K to 180 K (+28.57 %) |
| Sep 10 2004 | MDIT | Medite Cancer Diag ... | BERGQUIST DENNIS L | Chief Financial Off ... | Buy | P | 0.11 | 15,000 | 1,650 | 90,000 | 75 K to 90 K (+20.00 %) |
Page: 1